Dexcom appoints Glenn Boehnlein, former Stryker CFO, to board

DEXCOM INC

Board expanded to 13 directors; Boehnlein appointed effective Sept 10, 2026.
Boehnlein is former VP & CFO of Stryker; brings MedTech financial leadership.
Appointed to Operations & Innovation and Audit Committees.
Received initial RSU grant worth $500,000 vesting over 3 years; annual grant $347,500.
CEO Jake Leach cites Boehnlein's track record in growth and capital allocation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.